| Literature DB >> 27653506 |
Sangeeta Khare1,2, Kenneth L Drake3, Sara D Lawhon1, Jairo E S Nunes1, Josely F Figueiredo1, Carlos A Rossetti1, Tamara Gull1, Robin E Everts4, Harris A Lewin4, Leslie Garry Adams1.
Abstract
It has long been a quest in ruminants to understand how two very similar mycobacterial species, Mycobacterium avium ssp. paratuberculosis (MAP) and Mycobacterium avium ssp. avium (MAA) lead to either a chronic persistent infection or a rapid-transient infection, respectively. Here, we hypothesized that when the host immune response is activated by MAP or MAA, the outcome of the infection depends on the early activation of signaling molecules and host temporal gene expression. To test our hypothesis, ligated jejuno-ileal loops including Peyer's patches in neonatal calves were inoculated with PBS, MAP, or MAA. A temporal analysis of the host transcriptome profile was conducted at several times post-infection (0.5, 1, 2, 4, 8 and 12 hours). When comparing the transcriptional responses of calves infected with the MAA versus MAP, discordant patterns of mucosal expression were clearly evident, and the numbers of unique transcripts altered were moderately less for MAA-infected tissue than were mucosal tissues infected with the MAP. To interpret these complex data, changes in the gene expression were further analyzed by dynamic Bayesian analysis. Bayesian network modeling identified mechanistic genes, gene-to-gene relationships, pathways and Gene Ontologies (GO) biological processes that are involved in specific cell activation during infection. MAP and MAA had significant different pathway perturbation at 0.5 and 12 hours post inoculation. Inverse processes were observed between MAP and MAA response for epithelial cell proliferation, negative regulation of chemotaxis, cell-cell adhesion mediated by integrin and regulation of cytokine-mediated signaling. MAP inoculated tissue had significantly lower expression of phagocytosis receptors such as mannose receptor and complement receptors. This study reveals that perturbation of genes and cellular pathways during MAP infection resulted in host evasion by mucosal membrane barrier weakening to access entry in the ileum, inhibition of Ca signaling associated with decreased phagosome-lysosome fusion as well as phagocytosis inhibition, bias toward Th2 cell immune response accompanied by cell recruitment, cell proliferation and cell differentiation; leading to persistent infection. Contrarily, MAA infection was related to cellular responses associated with activation of molecular pathways that release chemicals and cytokines involved with containment of infection and a strong bias toward Th1 immune response, resulting in a transient infection.Entities:
Year: 2016 PMID: 27653506 PMCID: PMC5031438 DOI: 10.1371/journal.pone.0161946
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Invasion of Jejunal and Jejuno-ileal Mucosa by MAP and MAA.
Analysis of number of expressed genes changed during the MAP and MAA infection.
| Condition | Total Changed | Total Up/Down | 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs |
|---|---|---|---|---|---|---|---|---|
| MAP vs. PBS | 744 | 560 | 141 | 37 | 70 | 20 | 258 | 66 |
| 184 | 16 | 71 | 30 | 16 | 54 | 4 | ||
| MAA vs. PBS | 617 | 400 | 54 | 15 | 62 | 4 | 129 | 150 |
| 217 | 27 | 33 | 16 | 6 | 82 | 62 | ||
| Common in MAP & MAA | 141 | 106 | 17 | 11 | 11 | 1 | 27 | 16 |
| 35 | 4 | 13 | 5 | 2 | 9 | 1 | ||
| Unique in MAP | 622 | 468 | 124 | 26 | 59 | 19 | 231 | 50 |
| 154 | 12 | 58 | 25 | 14 | 45 | 3 | ||
| Unique in MAA | 484 | 304 | 37 | 4 | 51 | 3 | 102 | 134 |
| 180 | 23 | 20 | 11 | 4 | 73 | 61 |
Bayesian Z-score (filtered at |zscore| ≥ 1.96) with variance smoothing, outlier removal, and false discovery rate ≤ 0.5 shows the analysis of number of expressed genes changed during the MAP and MAA infection. Note: |z-score| > = 1.96, maximum false discovery rate at any one time point Q-value < = 0.05 (or < = 5%)
DBGGA Scoring Summaries for Pathways and Gene Ontologies for both the MAP and MAA Conditions.
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Activated | 47 | 0 | 2 | 3 | 13 | 126 | 144 |
| DBGGA Zscore Significantly Repressed | 41 | 0 | 1 | 0 | 0 | 18 | 59 |
| Total Significantly Perturbed | 88 | 0 | 3 | 3 | 13 | 144 | 162 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Activated | 13 | 1 | 2 | 14 | 0 | 79 | 89 |
| DBGGA Zscore Significantly Repressed | 28 | 0 | 0 | 2 | 0 | 30 | 57 |
| Total Significantly Perturbed | 41 | 1 | 2 | 16 | 0 | 109 | 128 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Activated | 682 | 8 | 81 | 400 | 766 | 2152 | 2718 |
| DBGGA Zscore Significantly Repressed | 415 | 2 | 1 | 15 | 62 | 384 | 823 |
| Total Significantly Perturbed | 1097 | 10 | 82 | 415 | 828 | 2536 | 3138 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Activated | 194 | 62 | 375 | 1538 | 99 | 1451 | 2543 |
| DBGGA Zscore Significantly Repressed | 219 | 24 | 16 | 179 | 13 | 622 | 984 |
| Total Significantly Perturbed | 413 | 86 | 391 | 1717 | 112 | 2073 | 3001 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Up regulated | 231 | 37 | 70 | 98 | 161 | 328 | 725 |
| DBGGA Zscore Significantly Down regulated | 253 | 25 | 48 | 45 | 64 | 228 | 591 |
| Total Significantly Perturbed | 484 | 62 | 118 | 143 | 225 | 556 | 1171 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significantly Up regulated | 141 | 64 | 134 | 193 | 69 | 270 | 688 |
| DBGGA Zscore Significantly Down regulated | 246 | 67 | 54 | 80 | 39 | 238 | 631 |
| Total Significantly Perturbed | 387 | 131 | 188 | 273 | 108 | 508 | 1144 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significant Up Regulated | 486 | 60 | 105 | 155 | 368 | 765 | 1531 |
| DBGGA Zscore Significant Down Regulated | 463 | 25 | 31 | 44 | 67 | 453 | 1038 |
| Total Significantly Perturbed | 949 | 85 | 136 | 199 | 435 | 1218 | 2381 |
| 0.5 hr | 1 hr | 2 hrs | 4 hrs | 8 hrs | 12 hrs | Total (Unique) | |
| DBGGA Zscore Significant Up Regulated | 275 | 119 | 205 | 388 | 85 | 606 | 1422 |
| DBGGA Zscore Significant Down Regulated | 517 | 71 | 55 | 115 | 30 | 517 | 1220 |
| Total Significantly Perturbed | 792 | 190 | 260 | 503 | 115 | 1123 | 2381 |
Summary of significantly perturbed pathways, Gene Ontologies, and associated genes passing 97.5% confidence threshold (DBGGA |zscore| ≥ 2.24). This table compares: (A) MAP versus PBS (uninfected) pathway scores; (B) MAA versus PBS pathway scores; (C) MAP versus PBS Gene Ontology scores; (D) MAA versus PBS Gene Ontology scores; (E) MAP versus PBS Pathway gene scores; (F) MAA versus PBS Pathway gene scores; (G) MAP versus PBS Gene Ontology gene scores; and (H) MAA versus PBS Gene Ontology gene scores.
Fig 2Heatmap comparison of significantly perturbed pathways (DBGGA |zscore| ≥ 2.24) for the (A) MAP vs PBS and (B) MAA vs PBS. Red indicates activation and green indicates repression. The gradient in color indicates magnitude of perturbation (i.e., higher |zscore|).
Fig 3Heatmap of pathway scores of a side-by-side comparison (by time point) between MAP vs PBS versus MAA vs PBS.
The heatmap compares MAP significantly perturbed pathways to the MAA condition. The selection of pathways was based on those that were found significant (DBGGA zscore ≥ 2.24) for the MAP condition at 30 minutes post infection. Red indicates activation and green indicates repression. The gradient in color indicates magnitude of perturbation (i.e., higher |zscore|).
Fig 4Heatmap of Gene Ontology scores of a side-by-side comparison (by time point) between MAP vs PBS versus MAA vs PBS.
The heatmap compares MAP significantly perturbed Gene Ontology categories to the MAA condition. This subset of GO categories were selected based on relevance to the immune response and are top scoring GO categories found significant (DBGGA zscore ≥ 2.24) for the MAP condition at 30 minutes post infection. Red indicates activation and green indicates repression. The gradient in color indicates magnitude of perturbation (i.e., higher |zscore|).
Early and Late Stage Pathway and Gene Ontologies Having Reversed and unique Perturbation States during MAP and MAA Interaction.
| Adherens junction | -2.03 | 2.07 | 0.00 | 0.00 |
| Focal adhesion | -1.98 | 1.42 | 0.00 | 0.25 |
| B cell receptor signaling pathway | 2.31 | -2.36 | 0.00 | 1.26 |
| TGF-beta signaling pathway | 2.95 | -1.57 | 0.00 | 0.88 |
| Calcium signaling pathway | 3.15 | -1.76 | 0.00 | 0.00 |
| Gap junction | 3.20 | -2.31 | 0.00 | -0.11 |
| complement activation | 2.96 | -1.83 | 0.73 | 1.65 |
| negative regulation of immune effector process | 2.13 | -2.07 | 0.00 | -0.94 |
| negative regulation of immune response | 2.10 | -3.45 | 0.76 | 1.08 |
| regulation of interferon-beta production | 4.58 | -2.39 | 0.00 | -2.34 |
| regulation of type 2 immune response | 2.95 | -2.24 | 0.00 | -0.45 |
| epithelial cell proliferation | -2.90 | 2.49 | 0.00 | 1.49 |
| Regulation of actin cytoskeleton | -2.15 | -0.01 | 3.64 | -2.81 |
| Melanogenesis | 2.97 | 0.00 | 3.56 | -2.93 |
| Hematopoietic cell lineage | 0.53 | 0.00 | 3.40 | -2.15 |
| Complement and coagulation cascades | 1.78 | 0.13 | 3.35 | -3.25 |
| Chemokine signaling pathway | -0.55 | 0.00 | 3.17 | -3.32 |
| Axon guidance | 0.73 | 0.00 | 2.99 | -3.52 |
| Cytokine-cytokine receptor interaction | 0.48 | 0.00 | 2.92 | -2.35 |
| Tight junction | 0.94 | 0.48 | 2.89 | -2.41 |
| NOD-like receptor signaling pathway | -0.62 | -0.18 | 2.74 | -2.87 |
| Cytosolic DNA-sensing pathway | 2.28 | 0.00 | 2.64 | -2.43 |
| Jak-STAT signaling pathway | -0.19 | 0.00 | 2.59 | -2.82 |
| Gap junction | -0.18 | 0.00 | -1.99 | 2.57 |
| B cell receptor signaling pathway | -0.28 | -0.38 | -2.02 | 2.61 |
| Phosphatidylinositol signaling system | -1.62 | 0.00 | -2.11 | 3.64 |
| Osteoclast differentiation | -0.37 | 0.33 | -2.96 | 2.50 |
| ErbB signaling pathway | -0.28 | -0.25 | -2.97 | 2.92 |
| Toll-like receptor signaling pathway | -0.43 | 0.00 | -3.04 | 2.12 |
| RIG-I-like receptor signaling pathway | 1.51 | 0.00 | -3.13 | 2.68 |
| Fc gamma R-mediated phagocytosis | -1.34 | -0.01 | 2.03 | -1.95 |
| phagocytosis | 2.00 | 2.00 | -2.34 | 3.17 |
| chemokine biosynthetic process | -2.14 | 0.72 | 3.59 | -4.09 |
| chemokine receptor activity | 0.00 | 0.00 | 3.20 | -1.87 |
| complement activation | -0.16 | 0.53 | 1.65 | -2.43 |
| leukocyte homeostasis | 2.16 | 0.00 | 2.49 | -3.36 |
| positive regulation of defense response to virus by host | 1.18 | 0.00 | -1.92 | 3.06 |
| positive regulation of humoral immune response | -2.12 | 0.73 | -3.00 | 3.21 |
| positive regulation of immunoglobulin mediated immune response | -1.75 | 0.13 | -1.98 | 2.60 |
| Complement and coagulation cascades | 3.13 | 1.17 | 0.00 | 0.75 |
| ABC transporters | 3.11 | -1.06 | 0.00 | 1.00 |
| Cytosolic DNA-sensing pathway | 2.85 | 1.51 | 0.00 | 1.25 |
| SNARE interactions in vesicular transport | 2.83 | -1.57 | 0.00 | 1.55 |
| Cytokine-cytokine receptor interaction | 2.50 | 0.86 | 0.00 | 0.03 |
| Notch signaling pathway | 2.32 | 1.40 | 0.00 | -0.05 |
| Hematopoietic cell lineage | 2.25 | 1.41 | 0.00 | -0.35 |
| Adipocytokine signaling pathway | 2.24 | -0.93 | 0.00 | 0.00 |
| mTOR signaling pathway | 2.15 | -0.59 | 0.00 | -1.32 |
| ErbB signaling pathway | 2.12 | -0.42 | 0.00 | 0.05 |
| Toll-like receptor signaling pathway | 2.12 | 1.68 | 0.00 | 1.23 |
| Aldosterone-regulated sodium reabsorption | -2.20 | -1.40 | 0.00 | -0.39 |
| Proteasome | -2.24 | -1.75 | 0.00 | -0.88 |
| Leukocyte transendothelial migration | -2.27 | -1.88 | 0.00 | 0.91 |
| Protein processing in endoplasmic reticulum | -2.56 | -1.90 | 0.00 | -0.87 |
| Vasopressin-regulated water reabsorption | -2.73 | -1.58 | 0.00 | 0.00 |
| Phosphatidylinositol signaling system | -2.82 | -1.44 | 0.00 | -1.00 |
| Tight junction | -2.93 | -1.89 | 0.00 | -0.67 |
| interferon-gamma-mediated signaling pathway | 3.25 | -1.46 | 0.00 | 1.39 |
| innate immune response in mucosa | 3.56 | 0.00 | 0.00 | 0.00 |
| antibacterial humoral response | 3.52 | 1.86 | 0.34 | -0.75 |
| regulation of immunoglobulin mediated immune response | 3.16 | 1.64 | -0.22 | 1.65 |
| neutrophil mediated immunity | 3.07 | -1.09 | 0.00 | 0.89 |
| adaptive immune response | 3.01 | 1.00 | 0.86 | 1.31 |
| complement activation | 2.96 | -1.83 | 0.73 | 1.65 |
| positive regulation of defense response to virus by host | 2.92 | 1.64 | -0.24 | 1.66 |
| myeloid leukocyte mediated immunity | 2.65 | -0.97 | 0.00 | -0.40 |
| chemokine receptor activity | 2.62 | -0.53 | 0.00 | -0.72 |
| positive regulation of innate immune response | 2.31 | 0.22 | 0.00 | -0.14 |
| leukocyte mediated immunity | 2.29 | -0.62 | 0.00 | -0.42 |
| complement activation, classical pathway | 2.22 | -1.29 | 1.02 | 1.84 |
| T cell mediated immunity | 2.18 | 1.35 | -0.85 | -0.31 |
| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2.14 | 0.83 | -0.17 | 0.62 |
| regulation of adaptive immune response | 2.14 | 1.36 | -0.52 | -0.19 |
| chemokine biosynthetic process | 2.13 | 1.18 | 0.00 | 2.28 |
| cell-cell adhesion mediated by integrin | -2.43 | 1.58 | 0.00 | 0.00 |
| ECM-receptor interaction | 1.97 | 0.00 | 3.17 | -1.72 |
| Vasopressin-regulated water reabsorption | 2.66 | 0.00 | 2.82 | 1.89 |
| Progesterone-mediated oocyte maturation | 0.64 | 0.00 | 2.73 | 1.89 |
| Proximal tubule bicarbonate reclamation | 1.05 | 0.00 | 2.71 | 1.62 |
| Cell adhesion molecules (CAMs) | 1.22 | 0.00 | 2.60 | 1.83 |
| ABC transporters | 0.95 | 0.00 | 2.27 | 1.76 |
| Renin-angiotensin system | -0.58 | 0.00 | -2.03 | -0.09 |
| mTOR signaling pathway | 1.07 | -0.32 | -3.20 | -1.92 |
| chemokine receptor activity | 0.00 | 0.00 | 3.20 | -1.87 |
| phagocytosis, engulfment | 0.00 | 0.00 | 3.04 | -1.74 |
| negative regulation of immune effector process | 0.84 | 0.00 | 3.04 | 1.19 |
| immune response-regulating cell surface receptor signaling pathway | 0.00 | -0.96 | 2.59 | 1.67 |
| innate immune response | 1.75 | 0.00 | 2.51 | 1.91 |
| negative regulation of immune response | -1.49 | -0.37 | 2.42 | 1.46 |
| lymphocyte activation involved in immune response | 1.48 | 0.00 | 2.36 | 0.72 |
| regulation of type 2 immune response | 0.00 | 0.00 | 2.32 | 1.57 |
| myeloid cell activation involved in immune response | -0.60 | 0.24 | 2.23 | 1.94 |
| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.00 | 0.00 | 2.18 | 1.72 |
| natural killer cell mediated immunity | 0.59 | 0.00 | -2.00 | 1.06 |
| MyD88-dependent toll-like receptor signaling pathway | 0.86 | 0.00 | -2.03 | 1.09 |
| regulation of T-helper 1 type immune response | 0.00 | 0.00 | -2.40 | 1.55 |
| neutrophil mediated immunity | 2.07 | 0.00 | -2.94 | -1.37 |
| humoral immune response mediated by circulating immunoglobulin | 2.10 | 0.38 | -3.46 | 1.23 |
| Regulation of actin cytoskeleton | 2.26 | -1.84 | 0.53 | 0.00 |
| Neuroactive ligand-receptor interaction | 2.04 | 1.83 | 0.33 | 0.00 |
| VEGF signaling pathway | -1.96 | 1.51 | 1.18 | 0.00 |
| Fc epsilon RI signaling pathway | -2.06 | 1.27 | 1.28 | 0.00 |
| Phagosome | -2.53 | -1.88 | 0.19 | 0.00 |
| Antigen processing and presentation | -2.14 | 1.65 | -0.57 | 0.00 |
| cytokine production involved in immune response | 3.14 | 1.86 | -1.30 | -0.20 |
| regulation of innate immune response | 2.50 | 1.81 | 1.53 | 0.00 |
| regulation of T-helper 1 type immune response | 2.18 | 1.49 | -0.61 | -0.77 |
| regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2.10 | 1.71 | -0.48 | -0.52 |
| type 2 immune response | -2.26 | 1.11 | -0.35 | 0.00 |
| T cell costimulation | 2.33 | 0.05 | -0.78 | 0.00 |
| interleukin-12 production | 2.19 | 1.55 | 1.19 | 0.00 |
| negative regulation of JAK-STAT cascade | -2.95 | -1.21 | -0.23 | -0.22 |
| Fc epsilon RI signaling pathway | -0.70 | 0.00 | 2.55 | -1.60 |
| p53 signaling pathway | 0.00 | -0.09 | 2.46 | -1.67 |
| Notch signaling pathway | 0.00 | -0.75 | -2.67 | -1.67 |
| positive regulation of production of molecular mediator of immune response | -0.41 | 0.00 | 3.00 | 0.63 |
| regulation of cytokine production involved in immune response | -0.24 | -0.64 | 2.28 | 1.63 |
| immune effector process | 0.00 | -0.34 | 1.98 | 0.93 |
| positive regulation of myeloid leukocyte cytokine production involved in immune response | 0.00 | 1.02 | -2.25 | 1.31 |
(A) Pathways and GO immune categories showing a reversal in states of activation or repression between MAP and MAA condition and separated by early and late stages. (B) The pathways and GO categories found to be unique to the MAP condition. (C) The pathways and GO categories found to be unique to the MAA condition separated into early and late stages.
Fig 5(A) The MAP-MAA condition comparison of the Tight Junction pathway Bayesian models with the state of gene expression and mechanistic genes shown for the 30 min post infection time point. (A) The same MAP-MAA condition comparison with the state of gene expression and mechanistic genes shown for the 30 min post infection time point. The legend indicates the meaning of node colors (representing a gene expression level) and arcs between connecting genes.
Common MAP and MAA Arcs and Mechanistic Genes in Tight Junction Pathway.
| Parent Gene | Parent Gene Description | Child cause | Childgene | MAP Norm. Arc Wt. | MAA Norm. Arc Wt. | Abs. Val. Difference | Correl. Direction | MAP 1st Mechanistic Time | MAP Parent Gene Score | MAP Child Gene Score | MAA 1st Mechanistic Time | MAA Parent Gene Score | MAA Child Gene Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PARD3 | par-3 partitioning defective 3 homolog (C. elegans) | JAM3 | junctional adhesion molecule 3 | 0.27 | 0.56 | 0.29 | positive | t = 30 | 0 | 2.62 | t = 720 | -2.9 | 0 |
| ACTB | actin, beta | MYL12A | myosin, light chain 12A, regulatory, non-sarcomeric | 0.2 | 0.38 | 0.18 | positive | t = 720 | 0 | 2.12 | t = 30 | -3.72 | 0 |
| CLDN7 | claudin 7 | MPDZ | multiple PDZ domain protein | -0.42 | -0.2 | 0.33 | negative | t = 60 | -3.17 | 0 | T = 480 | 2.4 | 0.81 |
| TJP1 | tight junction protein 1 | ACTG1 | actin, gamma 1 | 0.39 | 0.26 | 0.13 | positive | t = 60 | 0 | 2.04 | t = 60 | 0.74 | 2.57 |
| ACTG1 | actin, gamma 1 | MYH9 | myosin, heavy chain 9, non-muscle | 0.56 | 0.45 | 0.11 | positive | t = 60 | 2.04 | -1.37 | t = 60 | 2.57 | -1.55 |
| CDC42 | cell division cycle 42 (GTP binding protein, 25kDa) | PARD6B | par-6 partitioning defective 6 homolog beta (C. elegans) | 0.74 | 0.44 | 0.3 | positive | t = 720 | -3.53 | -0.81 | t = 240 | 2.53 | 0 |
| CLDN7 | claudin 7 | TJP3 | tight junction protein 3 (zona occludens 3) | 0.6 | 0.23 | 0.37 | positive | t = 60 | -3.17 | -1.81 | t = 480 | 2.4 | 0 |
| CDK4 | cyclin-dependent kinase 4 | CSDA | cold shock domain protein A | -0.36 | -0.2 | 0.16 | negative | t = 30 | -2.37 | -0.11 | t = 240 | 0 | -2.7 |
| CSNK2B | casein kinase 2, beta polypeptide | no child node | 0 | 0 | 0 | positive | t = 30 | -4.07 | 0 | t = 30 | -2.94 | 0 | |
| CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | no child node | 0 | 00 | positive | t = 30 | -2.27 | 0 | t = 240 | 2.06 | 0 | ||
| AKT2 | v-akt murine thymoma viral oncogene homolog 2 | no child node | 0 | 0 | 0 | positive | t = 60 | 2.08 | 0 | t = 720 | 2.47 | 0 | |
| PRKCZ | protein kinase C, zeta | no child node | 0 | 0 | 0 | positive | t = 240 | 2.72 | 0 | t = 30 | -2.75 | 0 | |
| EPB41L1 | erythrocyte membrane protein band 4.1-like 1 | no child node | 0 | 0 | 0 | positive | t = 30 | 2.03 | 0 | t = 240 | -2.36 | 0 |
Tight Junction Pathway Bayesian Model Interrogation Results of Gene-to-Gene Relationships and Mechanistic Genes found in common between the MAP and MAA conditions. See text for description of interrogation methods.
Unique MAA Arcs and Mechanistic Genes in Tight Junction Pathway.
| Parent Gene | Parent Gene Description | Child Gene | Child Gene Description | MAANorm. Arc Wt. | MAA Norm. Arc Wt. | Abs. Val. Difference | Correl. Direction | MAA 1st Mechanistic Time | MAA Parent Gene Score | MAA Child Gene Score | MAP 1st Mechanistic Time | MAP parent Gene Score | MAA Child Gene Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACTB | actin, beta | MYL7 | myosin, light chain 7, regulatory | 0.23 | -0.01 | 0.24 | reverse | t = 30 | -3.72 | 0 | t = 720 | 0 | 2.11 |
| ACTG1 | actin, gamma 1 | TJP2 | tight junction protein 2 (zona occludens 2) | -0.45 | -0.17 | 0.28 | negative | t = 30 | 0.03 | 2.02 | t = 60 | 2.04 | 0 |
| ACTB | actin, beta | MYH14 | myosin, heavy chain 14, non-muscle | 0.28 | 0.16 | 0.12 | positive | t = 30 | -3.72 | 0 | 0 | 0 | |
| ACTB | actin, beta | MYH9 | myosin, heavy chain 9, non-muscle | 0.58 | 0.42 | 0.16 | negative | t = 30 | -3.72 | 0 | 0 | 0 | |
| ACTB | actin, beta | MYH1 | myosin, heavy chain 1, skeletal muscle, adult | -0.29 | -0.44 | 0.15 | negative | t = 30 | -3.72 | 0 | 0 | 0 |
Tight Junction Pathway Bayesian Model Interrogation Results found unique to the MAA condition.
Fig 6(A) Heatmap of MAP and MAA condition comparison of DBGGA zscores for mechanistic genes in the Gap Junction, Adherens Junction, Tight Junction, and Focal Adhesion junction pathways. (B) Heatmap MAP and MAA condition comparison of DBGGA zscores for mechanistic genes in the Gene Ontology category “Epithelial cell proliferation”.
Fig 7Venn diagram comparison of the number of unique and common mechanistic genes found for the MAP and MAA conditions.
Only the mechanistic genes from the pathways and GO terms listed in Table 3 were used in creating this diagram.
Fig 8(A) Depiction of the summary conclusion for the MAP host immune and evasion responses. (B) Depiction of the summary conclusion for the MAA host immune response.
Unique MAP Arcs and Mechanistic Genes in Tight Junction Pathway.
| Parent Gene | Parent Gene Description | Child Gene | Child Gene Description | MAP Norm. Arc Wt. | MAP Norm. Arc Wt. | Abs. Val. Difference | Correl. Direction | MAP 1st Mechanistic Time | MAP Parent Gene Score | MAP Child Gene Score | MAP Child Gene Score | MAP Child Gene Score | MAA Child Gene Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACTN1 | actinin, alpha 1 | MAGI3 | membrane associated guanylate kinase, WW and PDZ domain containing 3 | 0.21 | -0.03 | 0.24 | reverse | t = 30 | 0.71 | 2.65 | t = 60 | 0 | 1.99 |
| CLDN7 | claudin 7 | TJP2 | tight junction protein 2 (zona occludens 2) | -0.43 | 0.15 | 0.58 | reverse | t = 60 | -3.17 | 0 | t = 30 | -0.92 | 2.02 |
| RRAS2 | related RAS viral (r-ras) oncogene homolog 2 | MLLT4 | myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 | -0.41 | 0.1 | 0.51 | reverse | t = 60 | -0.41 | 2.17 | t = 480 | -0.51 | -3.1 |
| ACTG1 | MYH14 | MYH14 | myosin, heavy chain 14, non-muscle | 0.3 | 0.1 | 0.2 | positive | t = 30 | -0.98 | 2.75 | t = 60 | 2.57 | -0.23 |
| PRKCB | protein kinase C, beta | ACTB | actin, beta | 0.27 | 0.1 | 0.17 | positive | t = 720 | -2.69 | 0 | t = 30 | 0 | -3.72 |
| PARD3 | par-3 partitioning defective 3 homolog (C. elegans) | F11R | F11 receptor | -0.46 | -0.18 | 0.28 | negative | t = 30 | 0 | 1.99 | t = 720 | -2.9 | -1.05 |
| TJP1 | tight junction protein 1 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 0.48 | 0.3 | 0.18 | positive | t = 30 | 0 | -4.29 | 0 | -1.38 | |
| CLDN7 | CLDN7 | TJP1 | tight junction protein 1 | 0.23 | 0.03 | 0.2 | positive | t = 60 | -3.17 | 0 | t = 480 | 2.4 | -0.69 |
| CLDN7 | CLDN7 | CLDN7 | InaD-like (Drosophila) | 0.47 | 0.12 | 0.35 | positive | t = 60 | -3.17 | 0 | t = 480 | 2.4 | 0 |
| ACTG1 | actin, gamma 1 | MYL9 | myosin, light chain 9, regulatory | 0.3 | 0.13 | 0.17 | positive | t = 60 | 2.04 | 0 | t = 60 | 2.57 | 0 |
| ACTN3 | actinin, alpha 3 | MAGI2 | membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2-like | 0.21 | 0.07 | 0.14 | positive | t = 120 | 0 | 3.05 | t = 120 | 0 | 2.98 |
| EPB41L3 | erythrocyte membrane protein band 4.1-like 3 | CASK | calcium/calmodulin-dependent serine protein kinase (MAGUK family) | 0.21 | 0.04 | 0.17 | positive | t = 30 | 2.62 | 0 | t = 30 | 2.02 | 0.6 |
| ACTG1 | actin, gamma 1 | MYL7 | myosin, light chain 7, regulatory | 0.38 | 0.17 | 0.21 | positive | t = 60 | 2.04 | -0.62 | t = 60 | 2.57 | -0.44 |
| PARD3 | par-3 partitioning defective 3 homolog (C. elegans) | IGSF5 | immunoglobulin superfamily, member 5 | 0.23 | 0.11 | 0.12 | positive | t = 720 | -2.71 | 0 | t = 720 | -2.9 | -0.53 |
| JAM3 | junctional adhesion molecule 3 | TJP1 | tight junction protein 1 | 0.29 | 0 | 0.29 | positive | t = 30 | 2.62 | 0 | 0 | 0 | |
| PRKCB | protein kinase C, beta | IGSF5 | immunoglobulin superfamily, member 5 | -0.24 | -0.13 | 0.11 | negative | t = 720 | -2.60 | 0 | 0.99 | -0.53 | |
| ACTN3 | actinin, alpha 3 | MAGI3 | membrane associated guanylate kinase, WW and PDZ domain containing 3 | -0.21 | 0.04 | 0.25 | reverse | t = 30 | 0 | 2.65 | t = 60 | 0 | 1.99 |
| PPP2R1A | protein phosphatase 2, regulatory subunit A, alpha | no child node | 0 | 0 | 0 | positive | t = 720 | 2.14 | 0 | 1.18 | 0 |
Tight Junction Pathway Bayesian Model Interrogation Results found unique to the MAP condition.